Arenegyr: Phase I started

MolMed began an open-label, dose-escalation, Italian Phase I trial (NGR013) to evaluate 60, 80, 100 and 120 µg/m 2 of IV NGR-hTNF given once every 3 weeks for 4 treatment cycles in 16 patients. ...